Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GENE202
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Sofinnova Partners
Deal Size : $52.0 million
Deal Type : Series B Financing
Genespire Raises €46.6M For Pediatric Gene Therapy Clinical Trials
Details : The financing will enable the development of GENE202, the company’s lead candidate, up to a Phase I/II clinical trial patients affected by methylmalonic acidemia.
Product Name : GENE202
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 24, 2024
Lead Product(s) : GENE202
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Sofinnova Partners
Deal Size : $52.0 million
Deal Type : Series B Financing
Lead Product(s) : MicroRNA-regulated lentiviral vectors
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Recipient : SR-Tiget
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the alliance, Genespire and SR-Tiget will study and further develop novel gene therapies, which have the unique potential to address severe unmet medical need and exploit gene editing and lentiviral vector technologies developed by SR-...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 13, 2020
Lead Product(s) : MicroRNA-regulated lentiviral vectors
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Recipient : SR-Tiget
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Gene Therapy
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Sofinnova Partners
Deal Size : $17.3 million
Deal Type : Series A Financing
Details : The funds will be used to advance Genespire’s leading-edge platform technologies towards the development of novel gene therapies in primary immunodeficiencies and metabolic genetic diseases.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 29, 2020
Lead Product(s) : Gene Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Sofinnova Partners
Deal Size : $17.3 million
Deal Type : Series A Financing